Soriatane© (Acitretin) - A - Detailing from Skin Therapy Letter

 

Soriatane© (Acitretin)

 

 

  Content:

EFFICACY

 

 

In extensive clinical trials, acitretin has been shown to be effective in treating severe psoriasis both as monotherapy and in combination with other therapies.

Psoriasis – Monotherapy

  • Best clinical response obtained in localized or generalized pustular psoriasis and in erythrodermic psoriasis
  • In some patients, an initial worsening of the disease may be observed, with an increase in erythema and the extent of lesions.
  • Low initial doses of 10 mg/day, progressively increased up to 50 mg/day, can avoid this undesirable effect.
  • Multicenter trials show around 75% of patients achieving a PASI 50 response rate and 50% achieving a PASI 75 response rate after 12 weeks of therapy (a 50% or 75% improvement in their baseline Psoriasis Area Severity Index (PASI) score, respectively)
  • One third of patients with plaque-type psoriasis attain complete remission with acitretin monotherapy

Psoriasis – Combination Therapy

  • Combining therapy with PUVA or UVB increases efficacy and limits treatment frequencies, duration and cumulative doses. This allows for a safer and less costly treatment
  • .
  • Complete clearing of plaque-type psoriasis may require additional therapy such as topical corticosteroids, topical vitamin D analogues, PUVA or UVB phototherapy
  • Can also be combined with a calcipotriol ointment, allowing for a lower total dose of acitretin and improved treatment outcomes


Next:   Compliance